Navigation Links
Missing Puma reveals cancer conundrum
Date:7/31/2010

Walter and Eliza Hall Institute researchers in Melbourne, Australia, have made a discovery that has upended scientists' understanding of programmed cell death and its role in tumour formation.

Programmed cell death, also called apoptosis, is an important process in human biology as it removes unwanted and damaged cells from our bodies. This process protects us against cancer development and autoimmune disease.

The research team's discovery, led by Professor Andreas Strasser from the institute's Molecular Genetics of Cancer Division, has implications for the understanding of how cancers develop and will inform the ongoing development of a new class of anti-cancer drugs called BH3 mimetics.

"Until now everybody believed that a failure of damaged cells to undergo suicide allowed mutated cells to proliferate, which contributes to tumour development," Professor Strasser said. "That's certainly still true but we discovered that, in certain settings, the opposite holds: the body's natural cell-suicide program can fuel tumour development."

The research team's experiments revealed that repeated cycles of cellular depletion and tissue regeneration, by activating stem cells, could promote tumour development.

In situations where the DNA in many cells is damaged, such as when the body is repeatedly exposed to low doses of radiation, there are repeated cycles of cell death in the body's tissues. "Attempts by the body's stem cells to repopulate the depleted tissue can then actually drive the tumour development," Professor Strasser said. "That's because the radiation, while killing many cells within a tissue, will create mutations in some of the surviving stem cells. When such abnormal (mutated) stem cells repopulate the tissue, they will divide many times and this can promote the development of tumours."

The research, done in collaboration with Dr Ewa Michalak, Dr Cassandra Vandenberg, Mr Alex Delbridge, Dr Li Wu, Dr Clare Scott and Professor Jerry Adams, is published in today's issue of the international journal Genes and Development.

Crucial to the team's research was an understanding of what happens to mice exposed to radiation when a gene called Puma is missing. "If normal mice (which have the Puma gene) are given a low dose of radiation it destroys around 80 per cent of the white blood cells," Professor Strasser said. "That does not kill the mouse but it does mean the stem cells in the bone marrow have to work extra hard to replenish the blood system. This can lead to the formation of tumours of white blood cells, called leukaemias, if the stem cells doing the repopulating have cancer-causing mutations.

"The surprise was that mice that don't carry the Puma gene are protected from this type of tumour development. Puma is essential for the death of cells that have damaged DNA. If mice don't have the Puma gene when they receive low doses of radiation the white blood cells are not destroyed, so you don't force mutated stem cells to become activated (and divide) to replenish the blood system."

Professor Strasser said the research suggested that the risk of cancer was increased in people who experienced cycles of tissue destruction followed by tissue re-population by stem cells. "Such cycles may account for the liver cancers frequently associated with viral (hepatitis C) infection or alcohol-related liver damage." The research also helps explain the so-called secondary cancers that sometimes arise in patients who were cured of their primary cancer by chemotherapeutic drugs that cause DNA damage."

The findings will also inform the ongoing development of a new class of anti-cancer drugs called BH3 mimetics. These drugs are designed to kill cancer cells. "Chronic exposure to such drugs could lead to the death of large numbers of normal cells that would then need to be replaced," Professor Strasser said. "In certain circumstances this could promote the development of secondary cancers, particularly if patients are receiving treatments such as chemotherapy or gamma-radiation that can lead to cancer-causing mutations in stem cells."


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. Missing: 2,000 elephants
2. Missing genes link to psoriasis
3. Missing piece of plant clock found
4. A missing enzyme conveys major heart protection in pre-clinical work
5. Fossil evidence of missing link in the origin of seals, sea lions, walruses found in Canadian Arctic
6. Yeast missing sex genes undergo unexpected sexual reproduction
7. New therapy substitutes missing protein in those with muscular dystrophy
8. Researchers restore missing protein in rare genetic brain disorder
9. Plants on steroids: Key missing link discovered
10. Cells can read damaged DNA without missing a beat
11. High-performance computing reveals missing genes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Missing Puma reveals cancer conundrum
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/21/2016)... March 22, 2016 Unique ... passcodes for superior security   ... provider of secure digital communications services, today announced it ... and offer enterprise customers, particularly those in the Financial ... and voice authentication within a mobile app, alongside, and ...
(Date:3/14/2016)... Florida , March 14, 2016 ... the growing mobile commerce market, announces the airing of a ... channels starting the week of March 21 st .  The ... CNBC, including its popular Squawk on the Street show. ... focused on the growing mobile commerce market, announces the airing ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a ... Board. Dr. Lamka will assist PathSensors in expanding the use of the company‚Äôs ... the CANARY® test platform for the detection of harmful pathogens, including a number ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, ... Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from ... and the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on ... of Catherine Moukheibir as Chairman of its Board of Directors. ... Jacques Garaud , who contributed to the rapid development of ... Catherine started her career in strategy consulting and investment ... London .  She held C-Suite level roles in some ...
Breaking Biology Technology: